The global Multiplex Biomarker Imaging Market is on an accelerated growth trajectory, with revenues reported at USD 532.8 million in 2023. Valued at USD 585.0 million in 2024, the market is projected to expand at a robust CAGR of 10.8%, reaching an impressive USD 1,631.4 million by 2034.
The increasing adoption of multiplex biomarker imaging technologies in precision medicine and oncology is a key driver of market growth. These technologies offer unparalleled capabilities in studying complex diseases, enabling simultaneous detection of multiple biomarkers and advancing personalized treatment strategies. Furthermore, ongoing innovations in imaging modalities and automation are enhancing workflow efficiency, fueling market demand.
The rise in research funding for cancer studies and the growing demand for advanced diagnostic tools in drug discovery and clinical trials are further propelling market expansion. Emerging economies are expected to contribute significantly, supported by improving healthcare infrastructure and investment in life sciences research.
Grab Your Complete Report Instantly – https://www.futuremarketinsights.com/reports/multiplex-biomarker-imaging-market
Key Takeaways:
- Market Size: Valued at USD 532.8 million in 2023, projected to grow to USD 1,631.4 million by 2034.
- Growth Rate: Expected to expand at a robust CAGR of 10.8% from 2024 to 2034.
- Market Drivers: Increasing demand for precision medicine, advances in imaging technology, and growth in cancer research funding.
- Emerging Trends: Adoption of automated workflows, expansion in emerging markets, and integration of multiplex imaging in clinical trials.
Growth Drivers
- Technological Advancements: Improvements in high-throughput imaging systems facilitate the simultaneous study of multiple biomarkers, enhancing diagnostic accuracy and efficiency.
- Rising Incidence of Complex Diseases: The increasing prevalence of diseases such as cancer and neurological disorders is driving the demand for extensive biomarker analysis, which is crucial for developing targeted therapies.
- Focus on Personalized Medicine: The growing emphasis on personalized medicine necessitates sophisticated imaging tools to tailor therapies to specific patient profiles, further fueling market growth.
- Increased Investment in Biomedical Research: Rising investments in healthcare infrastructure and research are expected to foster innovation and expand application areas for multiplex biomarker imaging.
Regional Insights
- The Asia-Pacific region, particularly China, is projected to experience significant growth, with a CAGR of 12.3% during the forecast period, driven by advancements in digital pathology and telemedicine.
- In North America, Canada is expected to lead with a CAGR of 11.4% by 2034.
Competitive Landscape
The multiplex biomarker imaging market competitive landscape is mildly competitive, with top companies pushing innovation. Potential investment opportunities in multiplex biomarker imaging technology and service providers with applications ranging from cancer to immunology and neurology.
Emerging players and strategic collaborations ratchet up competition, pushing the limits of precision medicine and driving fast advances in biomarker detection and analysis.
Company websites and investor presentations of leading players in the industry are anticipated to bring industry investment potential, which will in turn help the key players face multiplex biomarker imaging industry challenges. This will also boost the leading players in the industry and their industry share.
Recent Industry Developments
- In May 2024, llumina Inc. announced that part of their latest research would be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4. Highlights include data from several studies in partnership with Labcorp, demonstrating additional evidence to support the use of comprehensive genomic profiling (CGP) over single gene testing (SGT) and the most recent data supporting the development of Illumina’s molecular residual disease (MRD) assay, which is currently underway in collaboration with major In all, Illumina had 14 abstracts accepted for the conference.
- In April 2024, Merck intends to purchase Mirus Bio for USD 600 million. Mirus Bio, based in Madison, Wisconsin, focuses on the development and sale of transfection reagents. Transfection reagents, including Mirus Bio’s TransIT-VirusGEN®, help genetic material enter cells. The compounds are essential in the creation of viral vectors for cell and gene therapies.
Leading Multiplex Biomarker Imaging Brands
- PerkinElmer Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Abcam plc.
- Merck KGaA
- Illumina Inc.
- Leica BiosystemsNussloch GmbH
- Ventana Medical Systems, Inc.
- AushonBioSystems Ltd.
- MicroConstants, Inc.
- ToposNomos Ltd.
Key Segments of the Report
By Component Type:
The multiplex biomarker imagining industry is classified into instruments (quantitative pathology imaging system, immunofluorescence, multispectral imaging system and toponome imaging system), software and services (installation and integration services and maintenance services).
By Imaging Technique:
The multiplex biomarker imagining industry is classified into Immunohistochemistry (IHC) Assay, Fluorescent in Situ Hybridization (FISH) Assay and Tissue Microarray (TMA) Assay).
By Application:
The multiplex biomarker imagining industry is classified into research and clinical diagnostics.
By End User:
The multiplex biomarker imagining industry is classified into translation laboratories, biopharmaceutical companies and academic institutes.
By Region:
Analysis of the multiplex biomarker imagining industry has been carried out in key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube